Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020

SELL
$113.26 - $167.27 $6,682 - $9,868
-59 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$72.01 - $120.39 $4,248 - $7,103
59 New
59 $7,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Citizens Financial Group Inc Portfolio

Follow Citizens Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citizens Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citizens Financial Group Inc with notifications on news.